Shared genetic risk factors and their implications for treatment of IPF and systemic hypertension

Gina Parcesepe^{1,2}, Richard J Allen^{1,2}, Beatriz Guillen-Guio^{1,2}, Samuel Moss³, R Gisli Jenkins³, *Louise V Wain^{1,2} on behalf of the DEMISTIFI consortium

1. Department of Population Health Sciences, University of Leicester, Leicester, UK

2. NIHR Leicester Biomedical Research Centre, Leicester, UK

3. Margaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and Lung Institute, Imperial College London, London, UK

*Corresponding author

Abstract

More than 50% of individuals with idiopathic pulmonary fibrosis (IPF) have co-morbid hypertension. High blood pressure can lead to organ fibrosis or can be a consequence of artery stiffening due to fibrosis. Studies have implicated common processes, such as TGF- β signalling, in both traits' regulation. Our goal is to identify shared genetic risk factors for IPF and hypertension.

We analysed the genome-wide genetic correlation using LD Score Regression and the largest available genome-wide association studies of clinically defined IPF, and systolic and diastolic blood pressure (SBP and DBP, respectively). We then conducted a genome-wide colocalisation analysis to identify regions with a shared signal at $P<10^{-5}$ between IPF and either SBP or DBP.

There was no genome-wide correlation between IPF and SBP (correlation (95% CI) -0.077(-0.142, -0.011), P=0.022) or DBP (correlation (95% CI) -0.027(-0.093, 0.039), P=0.427). The genome-wide colocalisation identified 8 shared signals, 3 (near *MAD1L1*, *GOLPH3L/HORMAD1*, and at 17q21.31) had the same direction of effect on risk of IPF and hypertension and 5 (near *TERC*, *OBFC1*, *DEPTOR*, and at 7q22.1 and 6p21.2) had opposite effects.

These findings support that there may be shared fibrotic mechanisms between IPF and hypertension. The opposite effects of variants at specific loci highlight the need for caution when considering therapeutic targeting of these shared pathways for either disease.

Background

Idiopathic Pulmonary Fibrosis (IPF) is the most prevalent progressive idiopathic interstitial pneumonia (IIP) with a poor prognosis (median survival of 2.5-3.5 years from diagnosis and typically presents in older individuals (mean age=74). Systemic hypertension (high blood pressure) is highly prevalent and the leading contributor to all-cause death and disability worldwide. Hypertension is a risk factor for common comorbidities of IPF including ischaemic heart disease and more than 50% of individuals with IPF have systemic hypertension (defined as \geq 130 mm Hg systolic blood pressure (SBP) and/or \geq 80 mm Hg diastolic blood pressure (DBP) [1]). High blood pressure can lead to organ fibrosis or can be a consequence of artery stiffening due to fibrosis [2], and studies have implicated common pathways in both IPF and blood pressure regulation, such as TGF- β signaling and the reninangiotensin system (RAS) [3]. We hypothesised that there could be shared genetic risk factors for both traits. Understanding the pleiotropic effects of the genes involved could have benefits and implications for drug repurposing and development in treating both IPF itself, and comorbid conditions.

conditions. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2023.06.02.23290865; this version posted June 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Methods

We utilised the largest available genome-wide association studies (GWAS) of clinically defined IPF [4], and SBP and DBP [5], to examine both genome-wide and locus-specific overlap. LD score regression (LDSC) [6] was used to conduct genome-wide correlation. Genome-wide colocalisation was applied using the coloc R package [7] to identify regions with a shared signal at P<10⁻⁵ between IPF and either SBP or DBP; this was performed by identifying signals at P<10⁻⁵ in both datasets, and then performing colocalisation. We report signals with a posterior probability of >80% for a shared causal variant (coloc H4) as significant. Signals were mapped to gene either using prior published evidence or using Open Targets Genetics (OTG). OTG utilises distance from gene, eQTL, splice QTL and functional annotation to suggest the most likely variant-to-gene mapping.

Results

The IPF GWAS comprised 4,125 IPF cases and 20,464 controls. The SBP and DBP GWAS comprised 757,601 general population participants. There was no genome-wide correlation between IPF and SBP (correlation (95% CI) -0.077(-0.142, -0.011), P=0.022) or DBP (correlation (95% CI) -0.027(-0.093, 0.039), P=0.427). The genome-wide colocalisation analysis identified 18 regions of overlap of which 7 had a posterior probability of a shared causal variant >80% for IPF and blood pressure (Table 1). In addition, there was a shared signal at 17q21.31 for which colocalisation could not be reliably performed due to extended linkage disequilibrium across the region. However, the 17q21.31 signals for both IPF and blood pressure tagged an ancestral 1.5Mb genomic inversion [8] and so this was considered as a shared signal. Of the 8 shared signals, 3 (near *MAD1L1, GOLPH3L/HORMAD1*, and at 17q21.31) had the same direction of effect on risk of IPF and raised blood pressure (hypertension) and 5 (near *TERC, OBFC1, DEPTOR*, and at 7q22.1 and 6p21.2) had opposite effects with the allele associated with increased risk of IPF being associated with decreased blood pressure (and vice versa for the other allele) (Table 1).

Discussion

Our study identified shared genetic associations between IPF and blood pressure traits with genetic variants at some loci increasing the risk of both IPF and hypertension, whilst at other loci, the same genetic variants increased risk of one trait whilst being protective against the other.

The DEP Domain-Containing MTOR-Interacting Protein (*DEPTOR*) encodes an mTOR inhibitor and decreased *DEPTOR* gene expression was associated with increased risk of IPF [9]. Targeting the mTOR pathway has been highlighted as a promising new therapeutic avenue for IPF [10]. Our findings suggest that intervening on this pathway may have potential adverse effects on blood pressure.

There was a significant difference in sample size for the GWAS used in our analyses and this will have affected the statistical power to detect signals in the smaller IPF dataset. Our genome-wide approach that utilised a more lenient threshold than the commonly used genome-wide threshold of $P<5x10^{-8}$ will have partly mitigated this, but it is likely that more shared signals will be discovered as sample sizes increase. We only report signals with a single shared causal variant for IPF and blood pressure; it is plausible that nearby independent signals could exert their effect through the same nearby gene. It is likely that genetic effects may be tissue-specific and that different regulatory pathways may be involved in the expression of the same gene in different tissues.

Our findings provide support that drugs targeting shared mechanisms may have both anti-fibrotic and blood pressure lowering effects. However, the observation of opposite directions of effect for

some genes suggests that blood pressure monitoring may be warranted in clinical trials for new IPF drugs that target genes that share genetic associations with blood pressure.

Funding Statement

GP is funded by a Wellcome Trust Genomic Epidemiology and Public Health Genomics Doctoral Training Programme studentship (218505/Z/19/Z). This work was supported by an MRC-NIHR Strategic Priority Fund Consortium Award – (MR/W014491/1) DEMISTIFI Multi Morbidity: DEfining MechanIsms Shared across mulTI-organ Flbrotic disease to prevent the development of long-term multi-morbidity. BGG holds a Wellcome Trust Sir Henry Wellcome Postdoctoral Fellowship (221680/Z/20/Z). This is a summary of independent research funded by Wellcome Trust and MRC/NIHR and carried out at the National Institute for Health and Care Research (NIHR) Leicester Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the Wellcome Trust, MRC, the NIHR or the Department of Health and Social Care. RGJ is funded by an NIHR Research Professorship (RP-2017-08-ST2-014). This research used the SPECTRE High Performance Computing Facility at the University of Leicester. For the purpose of open access, a CC BY or equivalent licence will be applied to any author accepted manuscript version arising from this submission.

Competing interests

LVW reports funding from GSK, Pfizer, Orion Pharma and Genentech, outside of the submitted work. LVW reports consultancy for GSK, Galapagos and Boehringer-Ingelheim. RGJ has received grants from Astra Zeneca, Biogen, Galecto, GlaxoSmithKline, Nordic Biosciences, RedX and Pliant and consulting fees from AstraZeneca, Brainomix, Bristol Myers Squibb, Chiesi, Cohbar, Daewoong, GlaxoSmithKline, Veracyte, Resolution Therapeutics, Pliant and personal fees for advisory board participation or speaking fees Boehringer Ingelheim, Chiesi, Galapagos, Vicore, Roche, PatientMPower and AstraZeneca.

Data

IPF GWAS data are available from: <u>https://github.com/genomicsITER/PFgenetics</u>.

Blood pressure GWAS data are available from: https://www.ebi.ac.uk/gwas/publications/30224653

RSID	CHR	POS	Coded	Other	Coded allele frequency	IPF beta (se)	IPF Pvalue	SBP beta (se)	SBP Pvalue	H4 SBP (%)	DBP beta (se)	DBP Pvalue	H4 DBP (%)	Gene (source)
rs3738485	1	150552392	G	С	0.45	0.134 (0.027)	9.35x10 ⁻⁷	0.164 (0.030)	6.92x10⁻ ⁸	90.6	0.018 (0.017)	2.95x10 ⁻¹	75.9	GOLPH3L/ HORMAD1 (OTG)
rs12696304	3	169481271	G	С	0.28	0.256 (0.030)	8.45x10 ⁻¹⁸	-0.281 (0.035)	4.23x10 ⁻¹⁶	98.9	-0.088 (0.020)	9.94x10⁻ ⁶	48	TERC [4]
rs1214759	6	43352980	G	A	0.32	0.165 (0.029)	1.71x10 ⁻⁸	-0.333 (0.032)	4.79x10 ⁻²⁵	99.4	-0.135 (0.019)	2.51x10 ⁻¹³	98.6	6p21.2 <i>[4]</i>
rs12699415	7	1909479	А	G	0.42	0.236 (0.027)	7.85x10 ⁻¹⁸	0.228 (0.031)	1.82x10 ⁻¹³	84.9	0.124 (0.018)	3.30x10 ⁻¹²	75.3	MAD1L1 [4]
rs2897075	7	99630342	Т	С	0.38	0.263 (0.028)	1.77x10 ⁻²¹	-0.156 (0.031)	6.49x10 ⁻⁷	99	-0.101 (0.018)	1.96x10 ⁻⁸	<1.0	7q22.1 <i>[4]</i>
rs28513081	8	120934126	G	A	0.43	-0.180 (0.030)	1.22x10 ⁻⁹	na	na	na	0.084 (0.018)	1.58x10⁻ ⁶	89.6	DEPTOR [4]
rs7100920	10	105640978	т	С	0.49	0.17 (0.027)	1.67x10 ⁻¹⁰	-0.204 (0.030)	1.62x10 ⁻¹¹	92.4	-0.079 (0.017)	5.43x10⁻ ⁶	18.7	OBFC1 [4]
rs2077551	17	44214888	С	т	0.19	-0.351 (0.038)	1.92x10 ⁻²⁰	-0.271 (0.042)	8.75x10 ⁻¹¹	na	-0.146 (0.024)	1.24x10 ⁻⁹	na	17q21.31 <i>[4]</i>

Table 1: Colocalisation analyses results, stating the posterior probability that the traits are likely to share a causal variant.

RSID=reference SNP cluster ID, CHR=chromosome, POS=position (Build GRCh37), Coded=coded allele, Other=other allele, Coded allele frequency=coded allele frequency in IPF dataset, se=standard error, H4 is the posterior probability that the trait is likely to share a causal variant with IPF (probability >80% for a shared causal variant highlighted). Source is whether the gene information came from variant-to-gene mapping analyses from a prior paper [4] or Open Targets Genetics (OTG). OTG utilises distance from gene, eQTL, splice QTL and functional annotation to suggest the most likely variant-to-gene mapping.

na=not applicable. DEPTOR was not in the genome-wide colocalisation for SBP (not present at P<10⁻⁵ in dataset). Colocalisation was not performed for 17q21.31 due to extended linkage disequilibrium across the region.

medRxiv preprint doi: https://doi.org/10.1101/2023.06.02.23290865; this version posted June 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

References

- 1. Kreuter, M., et al., *Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis.* Thorax, 2017. **72**(2): p. 148-153.
- Zieman, S.J., V. Melenovsky, and D.A. Kass, *Mechanisms, Pathophysiology, and Therapy of Arterial Stiffness*. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005. 25(5): p. 932-943.
- 3. Tan, W.S.D., et al., *Targeting the renin-angiotensin system as novel therapeutic strategy for pulmonary diseases.* Curr Opin Pharmacol, 2018. **40**: p. 9-17.
- 4. Allen, R.J., et al., *Genome-wide association study across five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosis.* Thorax, 2022. **77**(8): p. 829-833.
- 5. Evangelou, E., et al., *Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits.* Nature genetics, 2018. **50**(10): p. 1412-1425.
- 6. Bulik-Sullivan, B.K., et al., *LD Score regression distinguishes confounding from polygenicity in genome-wide association studies.* Nature Genetics, 2015. **47**(3): p. 291-295.
- 7. Wallace, C., A more accurate method for colocalisation analysis allowing for multiple causal variants. PLOS Genetics, 2021. **17**(9): p. e1009440.
- 8. Boettger, L.M., et al., *Structural haplotypes and recent evolution of the human 17q21.31 region.* Nature Genetics, 2012. **44**(8): p. 881-885.
- 9. Allen, R.J., et al., *Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis.* American Journal of Respiratory and Critical Care Medicine, 2020. **201**(5): p. 564-574.
- 10. Platé, M., D. Guillotin, and R.C. Chambers, *The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis.* European Respiratory Review, 2020. **29**(157): p. 200269.